Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5098587 | 0.95 | MAPK1 (0.47) | MAPK1MEN1KMT2AALDH1A1HSD11B1 | |
| SCHEMBL5104768 | 0.86 | NPC1 (0.36) | MAPK1MEN1KMT2AALDH1A1HSD11B1 | |
| SCHEMBL14277204 | 0.79 | MAPK1 (0.49) | MAPK1MEN1KMT2AALDH1A1HSD11B1 | |
| SCHEMBL2667476 | 0.76 | MEN1 (0.53) | MAPK1MEN1KMT2AALDH1A1HSD11B1 | |
| SCHEMBL5098113 | 0.73 | ALDH1A1 (0.49) | MAPK1MEN1KMT2AALDH1A1HSD11B1 | |
| SCHEMBL5095918 | 0.72 | HSD11B1 (0.51) | MAPK1MEN1KMT2AALDH1A1HSD11B1 | |
| Trifluoroacetic Acid SCHEMBL6357956 | 0.70 | MAPK1 (0.47) | MAPK1MEN1KMT2AALDH1A1HSD11B1 | |
| SCHEMBL5092143 | 0.69 | HSD11B1 (0.62) | MAPK1MEN1KMT2AALDH1A1HSD11B1 | |
| SCHEMBL5095806 | 0.69 | MEN1 (0.49) | MAPK1MEN1KMT2AALDH1A1HSD11B1 | |
| SCHEMBL5092083 | 0.68 | MEN1 (0.48) | MAPK1MEN1KMT2AALDH1A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD17B1, HSD11B2 | MAPK1 358/4885MEN1 2285/4885KMT2A 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.